Sanofi Cancels Consumer Healthcare Business Spin-Off - Forbes
Oct 30, 2024 · Sanofi’s decision to cancel the spin-off of its consumer healthcare business and go ahead with a sell a 50% stake to CD&R reflects a strategic shift aimed at focusing more on its core ...
Sanofi in talks to sell 50% stake in consumer health business to …
Oct 11, 2024 · Sanofi has entered into talks to sell a controlling 50% stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier & Rice, the French pharmaceutical group said on...
Sanofi US News
Sep 27, 2024 · Sanofi and Regeneron are motivated to transform the treatment paradigm of COPD by examining the role different types of inflammation play in the disease progression through Dupixent, a first-in-class biologic, and the investigation of itepekimab.
Sanofi loses $21 bln in market value after dropping 2025 profit …
Oct 27 (Reuters) - Sanofi (SASY.PA) stock plunged on Friday, wiping 20 billion euros ($21 billion) off its market value, after it abandoned its 2025 profit target under a plan to list its...
Press Room - Sanofi US News
Oct 16, 2024 · FLUBLOK® (Influenza Vaccine) US label updated with one of Sanofi's largest flu vaccine safety studies in pregnant individuals. Read more.
Sanofi pushes ahead with €20bn consumer healthcare spin-off
Jun 2, 2024 · The move makes Sanofi the latest Big Pharma company to seek to separate low-margin, consumer businesses from divisions focused on innovative new medicines that offer higher returns.
Sanofi US Media Room - Home
Oct 24, 2024 · Welcome to the Sanofi US Media Room. Our Media Room is designed to provide reporters with company and product news, as well as key facts, figures and background information. To help you keep up with the latest news, we offer email alerts and RSS feeds.
Sanofi, Regeneron's Dupixent SBLA Accepted For FDA Review To …
22 hours ago · Sanofi and Regeneron are also studying dupilumab in a broad range of diseases driven in part by type-2 inflammation or other allergic processes in phase 3 studies. For More Such Health News, visit ...
Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a …
3 days ago · Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a Significant Shift in Chronic Obstructive Pulmonary Disease Treatment Landscape | DelveInsight PR Newswire Tue, Nov 12, 2024, 5:31 PM 10 ...
Regeneron, Sanofi Get New FDA Review of Dupixent for CSU
17 hours ago · The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of ...
- Some results have been removed